SCHEMBL3140629

SCHEMBL3140629

O=C1CN(Cc2cccc(B(O)O)c2)C(=O)N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 6/20 0.46
EPHX2 P34913 1/20 0.43
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
LPL P06858 2/20 0.40
LIPG Q9Y5X9 2/20 0.40
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HDAC6 Q9UBN7 2/20 0.37
GAA P10253 1/20 0.36
EPHX1 P07099 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
MAPK1 P28482 1/20 0.35
DCTPP1 Q9H773 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30065107 0.81 EPHX2 (0.47) ENPP2EPHX2DDB1CRBNMEN1
SCHEMBL3041858 0.78 POLB (0.62) ENPP2DDB1CRBNLPLLIPG
SCHEMBL5182904 0.78 EPHX2 (0.47) EPHX2DDB1CRBNMEN1POLB
SCHEMBL31768 0.77 CYP2D6 (0.54) EPHX2DDB1CRBNMEN1POLB
SCHEMBL1011633 0.76 DDB1 (0.69) ENPP2EPHX2DDB1CRBNMEN1
SCHEMBL9850086 0.76 DDB1 (0.69) ENPP2EPHX2DDB1CRBNMEN1
SCHEMBL9850110 0.75 DDB1 (0.67) ENPP2EPHX2DDB1CRBNMEN1
SCHEMBL13336442 0.74 PARP1 (0.46) ENPP2LPLLIPGMEN1POLB
SCHEMBL31773 0.73 LOXL2 (0.52) MAPTHDAC6KDM4EALDH1A1
SCHEMBL4655351 0.73 ENPP2 (0.51) ENPP2LPLLIPGMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288536-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-16 US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 US disclosed
EP-1812439-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2007-08-01 EP disclosed
WO-2006044687-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216765-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 ENPP2 1660/4885EPHX2 3277/4885DDB1 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.